COX-2 expression in ovarian cancer: an updated meta-analysis

Haiming Sun; Xuelong Zhang; Donglin Sun; Xueyuan Jia; Lidan Xu; Yuandong Qiao; Yan Jin

doi:10.18632/oncotarget.21538

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of Concern

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

COX-2 expression in ovarian cancer: an updated meta-analysis

Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao and Yan Jin _

PDF | HTML | How to cite

Oncotarget. 2017; 8:88152-88162. https://doi.org/10.18632/oncotarget.21538

Metrics: PDF 1580 views | HTML 3829 views | ?

Abstract

Haiming Sun1,2, Xuelong Zhang1, Donglin Sun1, Xueyuan Jia1, Lidan Xu1, Yuandong Qiao1 and Yan Jin1

1Laboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China

2National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA

Correspondence to:

Yan Jin, email: [email protected].

Keywords: COX-2, ovarian cancer, meta-analysis, prognosis

Received: February 24, 2017 Accepted: July 12, 2017 Published: October 04, 2017

ABSTRACT

The prognostic role of COX-2 expression in ovarian cancer patients has been studied for years, while results remain controversial. Thus we performed a meta-analysis to evaluate the prognostic impact of COX-2 expression on survival of ovarian cancer patients. The databases PubMed, Embase and CNKI were searched. Summary hazard ratio (HR) and 95% confidence intervals (CIs) were calculated to analyze the correlations between COX-2 expression and overall survival (OS), and disease-free survival (DFS). A total of 1,867 patients from 18 studies were enrolled in the final analysis. The results showed that patients with higher COX-2 expression had a poor OS (HR: 1.48; 95% CI: 1.19-1.85) and DFS (HR: 1.81, 95% CI: 1.28-2.55). Subgroup analysis showed that there had significant associations between COX-2 expression and survival rate in most of the subgroups. Furthermore, there were significant associations between COX-2 expression and several clinical parameters such as FIGO stage, histological type and age. These results showed the patients with higher COX-2 expression had a significantly poorer survival rate, COX-2 expression had the potential to be a prognostic marker of ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21538

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

COX-2 expression in ovarian cancer: an updated meta-analysis

Abstract